

Ricardo Blanco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8303342/publications.pdf>

Version: 2024-02-01

404
papers

14,247
citations

25034

57
h-index

30087

103
g-index

417
all docs

417
docs citations

417
times ranked

11531
citing authors

#	ARTICLE	IF	CITATIONS
1	Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. <i>New England Journal of Medicine</i> , 2015, 373, 2534-2548.	27.0	803
2	Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. <i>Lancet, The</i> , 2013, 381, 451-460.	13.7	610
3	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 79-87.	0.9	454
4	Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. <i>New England Journal of Medicine</i> , 2017, 377, 1525-1536.	27.0	405
5	Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu. <i>Arthritis and Rheumatism</i> , 2011, 63, 609-621.	6.7	369
6	Permanent visual loss and cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment. <i>Arthritis and Rheumatism</i> , 1998, 41, 1497-1504.	6.7	367
7	Henoch-Schönlein purpura in adulthood and childhood. Two different expressions of the same syndrome. <i>Arthritis and Rheumatism</i> , 1997, 40, 859-864.	6.7	365
8	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2317-2327.	13.7	316
9	Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients. <i>Ophthalmology</i> , 2012, 119, 1575-1581.	5.2	207
10	Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 722-727.	0.9	190
11	Strokes at Time of Disease Diagnosis in a Series of 287 Patients With Biopsy-Proven Giant Cell Arteritis. <i>Medicine (United States)</i> , 2009, 88, 227-235.	1.0	189
12	Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. <i>Ophthalmology</i> , 2018, 125, 757-773.	5.2	178
13	Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1544-1549.	0.9	173
14	Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. <i>Arthritis Research and Therapy</i> , 2017, 19, 285.	3.5	161
15	Cutaneous Vasculitis in Children and Adults. <i>Medicine (United States)</i> , 1998, 77, 403-418.	1.0	148
16	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
17	Secukinumab efficacy in anti-TNF-naïve and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 571-592.	0.9	137
18	Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 668-675.	5.6	129

#	ARTICLE	IF	CITATIONS
19	Clinical Features and Outcome of 95 Patients With Hypersensitivity Vasculitis. <i>American Journal of Medicine</i> , 1997, 102, 186-191.	1.5	126
20	Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 1607-1620.	5.6	126
21	Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1764-1770.	0.9	123
22	Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 22-27.	3.4	123
23	Relapses and Recurrences in Giant Cell Arteritis. <i>Medicine (United States)</i> , 2011, 90, 186-193.	1.0	122
24	The High Prevalence of Subclinical Atherosclerosis in Patients With Ankylosing Spondylitis Without Clinically Evident Cardiovascular Disease. <i>Medicine (United States)</i> , 2009, 88, 358-365.	1.0	121
25	Henoch-Schönlein Purpura in Northern Spain. <i>Medicine (United States)</i> , 2014, 93, 106-113.	1.0	117
26	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). <i>Arthritis Research and Therapy</i> , 2018, 20, 47.	3.5	117
27	Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. <i>British Journal of Rheumatology</i> , 2004, 43, 655-657.	2.3	115
28	Efficacy of Tocilizumab in Conventional Treatment-Refractory Adult-Onset Still's Disease: Multicenter Retrospective Open-Label Study of Thirty-Four Patients. <i>Arthritis and Rheumatology</i> , 2014, 66, 1659-1665.	5.6	115
29	Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1170-1173.	0.9	115
30	Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 717-723.	3.4	114
31	Development of sarcoidosis during etanercept therapy. <i>Arthritis and Rheumatism</i> , 2006, 55, 817-820.	6.7	110
32	Anti-TNF- α therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients. <i>Rheumatology</i> , 2014, 53, 2223-2231.	1.9	109
33	Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. <i>Autoimmunity Reviews</i> , 2016, 15, 1013-1030.	5.8	107
34	Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2018, 20, 100.	3.5	102
35	Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 110-120.	5.6	100
36	Urine metabolome profiling of immune-mediated inflammatory diseases. <i>BMC Medicine</i> , 2016, 14, 133.	5.5	97

#	ARTICLE	IF	CITATIONS
37	Cardiovascular Events in Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2015, 94, e1183.	1.0	96
38	Successful treatment of refractory Schnitzler syndrome with anakinra: Comment on the article by Hawkins et al. <i>Arthritis and Rheumatism</i> , 2005, 52, 2226-2227.	6.7	94
39	Efficacy of Anakinra in Refractory Adult-Onset Still's Disease. <i>Medicine (United States)</i> , 2015, 94, e1554.	1.0	93
40	Adult-onset Still's disease: Advances in the treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 222-238.	3.3	91
41	Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study. <i>Rheumatology</i> , 2018, 57, 856-864.	1.9	88
42	Giant Cell Arteritis: Epidemiology, Diagnosis, and Management. <i>Current Rheumatology Reports</i> , 2010, 12, 436-442.	4.7	83
43	Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. <i>American Journal of Ophthalmology</i> , 2019, 200, 85-94.	3.3	81
44	Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study. <i>Arthritis Care and Research</i> , 2017, 69, 1020-1029.	3.4	79
45	Long-term Successful Adalimumab Therapy in Severe Hidradenitis Suppurativa. <i>Archives of Dermatology</i> , 2009, 145, 580-4.	1.4	78
46	Anti-TNF- α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 361-368.	3.4	78
47	Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 95-101.	3.4	77
48	Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases. <i>Arthritis and Rheumatology</i> , 2019, 71, 2081-2089.	5.6	74
49	NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. <i>Atherosclerosis</i> , 2012, 224, 426-429.	0.8	72
50	Genetics of immunoglobulin-A vasculitis (Henoch-Schönlein purpura): An updated review. <i>Autoimmunity Reviews</i> , 2018, 17, 301-315.	5.8	72
51	Risk Factors and Predictive Models of Giant Cell Arteritis in Polymyalgia Rheumatica. <i>American Journal of Medicine</i> , 1997, 102, 331-336.	1.5	71
52	Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. <i>RMD Open</i> , 2017, 3, e000592.	3.8	68
53	Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 126-135.	3.4	66
54	Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1279-1284.	0.9	64

#	ARTICLE	IF	CITATIONS
55	Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. <i>Rheumatology</i> , 2020, 59, 3906-3916.	1.9	64
56	Relapses in patients with Henoch-Schönlein purpura. <i>Medicine (United States)</i> , 2016, 95, e4217.	1.0	63
57	Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 720-727.	3.4	63
58	Deficiency of the NF- κ B Inhibitor Caspase Activating and Recruitment Domain 8 in Patients with Rheumatoid Arthritis Is Associated with Disease Severity. <i>Journal of Immunology</i> , 2007, 179, 4867-4873.	0.8	62
59	Circulating cytokines in active polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 263-269.	0.9	58
60	Psychometric characteristics of the Spanish version of instruments to measure neck pain disability. <i>BMC Musculoskeletal Disorders</i> , 2008, 9, 42.	1.9	57
61	Anti-TNF therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1325-1330.	2.4	57
62	Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsaKE 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 351-358.	0.9	56
63	Insufficiency fractures of the tibia and fibula. <i>Seminars in Arthritis and Rheumatism</i> , 1999, 28, 413-420.	3.4	55
64	Late-onset systemic lupus erythematosus in Northwestern Spain: differences with early-onset systemic lupus erythematosus and literature review. <i>Lupus</i> , 2012, 21, 1135-1148.	1.6	55
65	The Spectrum of Paraneoplastic Cutaneous Vasculitis in a Defined Population. <i>Medicine (United States)</i> , 2011, 90, 350-358.	1.0	55
66	Insulin resistance in hidradenitis suppurativa: a case-control study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 820-824.	2.4	55
67	Tocilizumab in refractory aortitis: study on 16 patients and literature review. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S79-89.	0.8	55
68	Systemic Lupus Erythematosus in Northwestern Spain. <i>Medicine (United States)</i> , 2011, 90, 350-358.	1.0	54
69	Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience. <i>Mediators of Inflammation</i> , 2014, 2014, 1-5.	3.0	54
70	HLA-DRB1 allele distribution in polymyalgia rheumatica and giant cell arteritis: Influence on clinical subgroups and prognosis. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 454-464.	3.4	53
71	Analysis of the common genetic component of large-vessel vasculitides through a meta-immunochip strategy. <i>Scientific Reports</i> , 2017, 7, 43953.	3.3	52
72	Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1882-1886.	0.9	51

#	ARTICLE	IF	CITATIONS
73	Anti-tumor necrosis factor- α therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study. <i>Journal of Dermatology</i> , 2016, 43, 1267-1272.	1.2	51
74	Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease. <i>Ophthalmology</i> , 2018, 125, 1444-1451.	5.2	50
75	Comprehensive Description of Clinical Characteristics of a Large Systemic Lupus Erythematosus Cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) With Emphasis on Complete Versus Incomplete Lupus Differences. <i>Medicine (United States)</i> , 2015, 94, e267.	1.0	48
76	Genetic Analysis with the Immunochip Platform in Behçet Disease. Identification of Residues Associated in the HLA Class I Region and New Susceptibility Loci. <i>PLoS ONE</i> , 2016, 11, e0161305.	2.5	48
77	Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. <i>Mediators of Inflammation</i> , 2013, 2013, 1-6.	3.0	47
78	Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review. <i>Autoimmunity Reviews</i> , 2021, 20, 102830.	5.8	47
79	Urticarial Vasculitis in Northern Spain. <i>Medicine (United States)</i> , 2014, 93, 53-60.	1.0	46
80	Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS). <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 329-335.	1.2	45
81	¹⁸ F-FDG PET/CT in the follow-up of large-vessel vasculitis: A study of 37 consecutive patients. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 530-537.	3.4	45
82	Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. <i>Arthritis and Rheumatism</i> , 1996, 39, 1016-1020.	6.7	44
83	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. <i>Scientific Reports</i> , 2017, 7, 5088.	3.3	44
84	IgA Vasculitis: Genetics and Clinical and Therapeutic Management. <i>Current Rheumatology Reports</i> , 2018, 20, 24.	4.7	44
85	Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 355-364.	0.9	44
86	Dysphagia with Multiple Autoimmune Disease. <i>Clinical Rheumatology</i> , 2000, 19, 321.	2.2	43
87	Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases. <i>Rheumatology</i> , 2015, 54, 77-82.	1.9	42
88	Certolizumab Pegol, a New Anti-TNF- α in the Armamentarium against Ocular Inflammation. <i>Ocular Immunology and Inflammation</i> , 2016, 24, 1-6.	1.8	41
89	Biological therapy for systemic vasculitis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 542-557.	3.4	41
90	SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2013, 15, R91.	3.5	40

#	ARTICLE	IF	CITATIONS
91	Assessment of aortitis by semiquantitative analysis of 180-min 18F-FDG PET/CT acquisition images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2319-2324.	6.4	40
92	Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S54-7.	0.8	37
93	Association of the methionine sulfoxide reductase A rs10903323 gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2012, 41, 350-353.	1.1	36
94	Influence of the IL17A locus in giant cell arteritis susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1742-1745.	0.9	36
95	Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2816.	2.4	36
96	Study of Association of CD40-CD154 Gene Polymorphisms with Disease Susceptibility and Cardiovascular Risk in Spanish Rheumatoid Arthritis Patients. <i>PLoS ONE</i> , 2012, 7, e49214.	2.5	36
97	Brief Report: Association of HLA-DRB1*01 With IgA Vasculitis (Henoch-Schönlein). <i>Arthritis and Rheumatology</i> , 2015, 67, 823-827.	5.6	35
98	Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis. <i>Scientific Reports</i> , 2016, 6, 29713.	3.3	34
99	Adipokines, Biomarkers of Endothelial Activation, and Metabolic Syndrome in Patients with Ankylosing Spondylitis. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	33
100	Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. <i>Arthritis Research and Therapy</i> , 2015, 17, 102.	3.5	33
101	Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review. <i>Ocular Immunology and Inflammation</i> , 2017, 25, 609-614.	1.8	33
102	Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. <i>ACR Open Rheumatology</i> , 2020, 2, 294-299.	2.1	33
103	Expression and function of toll-like receptors in peripheral blood mononuclear cells of patients with polymyalgia rheumatica and giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1677-1683.	0.9	32
104	Sex differences in patients with systemic lupus erythematosus from Northwest Spain. <i>Rheumatology International</i> , 2014, 34, 11-24.	3.0	32
105	Drug-associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center. <i>Journal of Rheumatology</i> , 2014, 41, 2201-2207.	2.0	32
106	TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 850-5.	0.8	32
107	Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S44-53.	0.8	32
108	Carotid plaques as predictors of cardiovascular events in patients with Rheumatoid Arthritis. Results from a 5-year-prospective follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1333-1338.	3.4	31

#	ARTICLE	IF	CITATIONS
109	Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 608-615.	3.4	31
110	Cloxacillin-based therapy in severe septic bursitis: Retrospective study of 82 cases. <i>Joint Bone Spine</i> , 2009, 76, 665-669.	1.6	30
111	Clinical Manifestations and Outcomes of Syphilis-associated Uveitis in Northern Spain. <i>Ocular Immunology and Inflammation</i> , 2016, 24, 1-6.	1.8	30
112	High prevalence of non-alcoholic fatty liver disease among hidradenitis suppurativa patients independent of classic metabolic risk factors. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2131-2136.	2.4	30
113	Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. <i>ACR Open Rheumatology</i> , 2020, 2, 119-127.	2.1	30
114	Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. <i>Clinical and Experimental Dermatology</i> , 2007, 32, 672-674.	1.3	29
115	<i>CARD8</i> rs2043211 (p.C10X) Polymorphism Is Not Associated with Disease Susceptibility or Cardiovascular Events in Spanish Rheumatoid Arthritis Patients. <i>DNA and Cell Biology</i> , 2013, 32, 28-33.	1.9	29
116	Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2015, 17, 55.	3.5	29
117	Anti-TNF therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 92-95.	2.4	29
118	Mutational profile of rare variants in inflammasome-related genes in Behçet disease: A Next Generation Sequencing approach. <i>Scientific Reports</i> , 2017, 7, 8453.	3.3	29
119	Early large vessel systemic vasculitis in adults. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101424.	3.3	29
120	Hypertrophic Osteoarthropathy Secondary to Vascular Prosthesis Infection. <i>Medicine (United States)</i> , 2006, 85, 183-191.	1.0	28
121	Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry. <i>Rheumatology</i> , 2016, 55, 1243-1250.	1.9	28
122	Carga y costes directos de la uveítis no infecciosa en España. <i>Reumatología Clínica</i> , 2016, 12, 196-200.	0.5	28
123	Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000410.	3.8	28
124	Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study. <i>Arthritis Care and Research</i> , 2017, 69, 38-45.	3.4	27
125	Cross-phenotype analysis of ImmunoChip data identifies <i>KDM4C</i> as a relevant locus for the development of systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 589-595.	0.9	27
126	Acute reversible hypoxemia in systemic lupus erythematosus: a new syndrome or an index of disease activity?. <i>Lupus</i> , 1995, 4, 259-262.	1.6	26

#	ARTICLE	IF	CITATIONS
127	The ZC3HC1 rs11556924 polymorphism is associated with increased carotid intima-media thickness in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2013, 15, R152.	3.5	26
128	Osteoprotegerin Concentrations Relate Independently to Established Cardiovascular Disease in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 39-45.	2.0	26
129	Trial of Tocilizumab in Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2017, 377, 1493-1495.	27.0	26
130	Identification of a 3' UTR Untranslated Genetic Variant of <i>RARB</i> Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 351-360.	5.6	26
131	Decreased expression of methylene tetrahydrofolate reductase (MTHFR) gene in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 106-10.	0.8	26
132	Changes in peripheral blood lymphocyte subsets in elderly subjects are associated with an impaired function of the hypothalamic-pituitary-adrenal axis. <i>Mechanisms of Ageing and Development</i> , 2002, 123, 1477-1486.	4.6	25
133	Hypothalamic-pituitary-adrenocortical axis function in patients with polymyalgia rheumatica and giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2003, 32, 266-272.	3.4	25
134	Clinical disease activity and titers of anti-dsDNA antibodies measured by an automated immunofluorescence assay in patients with systemic lupus erythematosus. <i>Lupus</i> , 2005, 14, 505-509.	1.6	25
135	Interleukin-1RN gene polymorphisms in elderly patients with rheumatic inflammatory chronic conditions: Association of IL-1RN*2/2 Genotype with polymyalgia rheumatica. <i>Human Immunology</i> , 2009, 70, 49-54.	2.4	25
136	Anti-TNF- α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients. <i>Rheumatology International</i> , 2015, 35, 2069-2078.	3.0	25
137	Relationship of Leptin with adiposity and inflammation and Resistin with disease severity in Psoriatic patients undergoing anti-TNF- α therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1995-2001.	2.4	25
138	18F-FDG PET/CT for the detection of large vessel vasculitis in patients with polymyalgia rheumatica. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2015, 34, 275-281.	0.0	25
139	Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 69-75.	0.8	25
140	Association of haplotypes of the TLR8 locus with susceptibility to Crohn's and Behçet's diseases. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S117-22.	0.8	24
141	Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy. <i>British Journal of Rheumatology</i> , 2003, 42, 1055-1061.	2.3	23
142	Evidence of association of the <i>NLRP1</i> gene with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 628-630.	0.9	23
143	Lack of Association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and Carotid Intima-Media Thickness, Carotid Plaques, and Cardiovascular Disease in Patients with Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-6.	3.0	23
144	Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis. <i>Scientific Reports</i> , 2016, 6, 31979.	3.3	23

#	ARTICLE	IF	CITATIONS
145	Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER). <i>Rheumatology</i> , 2021, 60, 1793-1803.	1.9	23
146	Successful effect of tocilizumab in anti-TNF- α -induced palmoplantar pustulosis in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2012, 79, 510-513.	1.6	22
147	Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: A review. <i>Seminars in Arthritis and Rheumatism</i> , 2001, 30, 257-271.	3.4	21
148	Association of acid phosphatase locus 1*C allele with the risk of cardiovascular events in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2011, 13, R116.	3.5	21
149	Lack of association between IL6 single nucleotide polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis. <i>Atherosclerosis</i> , 2011, 219, 655-658.	0.8	21
150	Lack of Association Between TLR4 rs4986790 Polymorphism and Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis. <i>DNA and Cell Biology</i> , 2012, 31, 1214-1220.	1.9	21
151	Protective Role of the Interleukin 33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Rheumatoid Arthritis Patients. <i>PLoS ONE</i> , 2015, 10, e0143153.	2.5	21
152	Zoledronic Acid Treatment in Primary Bone Marrow Edema Syndrome. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2017, 31, 52-56.	0.8	21
153	Behçet's disease and genetic interactions between HLA-B*51 and variants in genes of autoinflammatory syndromes. <i>Scientific Reports</i> , 2019, 9, 2777.	3.3	21
154	Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet's disease associated uveitis: a systematic review. <i>Rheumatology International</i> , 2019, 39, 47-58.	3.0	21
155	Role of rs1343151 IL23R and rs3790567 IL12RB2 Polymorphisms in Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2011, 38, 889-892.	2.0	20
156	Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 720-729.	1.6	20
157	Prevalence and clinical features of psoriatic arthritis in psoriasis patients in Spain. Limitations of PASE as a screening tool. <i>European Journal of Dermatology</i> , 2015, 25, 57-63.	0.6	20
158	Standardization procedure for flow cytometry data harmonization in prospective multicenter studies. <i>Scientific Reports</i> , 2020, 10, 11567.	3.3	20
159	Selective T cell receptor decrease in peripheral blood T lymphocytes of patients with polymyalgia rheumatica and giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 54-60.	0.9	19
160	Influence of CD40 rs1883832 Polymorphism in Susceptibility to and Clinical Manifestations of Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2010, 37, 2076-2080.	2.0	19
161	Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, R146.	3.5	19
162	The Framingham Score and the Systematic Coronary Risk Evaluation at Low Cutoff Values Are Useful Surrogate Markers of High-risk Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 486-494.	2.0	19

#	ARTICLE	IF	CITATIONS
163	5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e339-e346.	3.9	19
164	Atherosclerotic disease in axial spondyloarthritis: increased frequency of carotid plaques. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 315-20.	0.8	19
165	Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 465-473.	0.8	19
166	Demyelinating disease and cutaneous lymphocytic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2006, 35, 322-323.	1.1	18
167	A deletion at ADAMTS9-MAG11 locus is associated with psoriatic arthritis risk. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1875-1881.	0.9	18
168	New insights into the genetic component of non-infectious uveitis through an ImmunoChip strategy. <i>Journal of Medical Genetics</i> , 2017, 54, 38-46.	3.2	18
169	Development of an activity disease score in patients with uveitis (LIVEDAI). <i>Rheumatology International</i> , 2017, 37, 647-656.	3.0	18
170	Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa. <i>Archives of Dermatological Research</i> , 2020, 312, 595-600.	1.9	18
171	Angiotensin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 761-6.	0.8	18
172	Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 864-8.	0.8	18
173	Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. <i>Rheumatology and Therapy</i> , 2022, 9, 521-539.	2.3	18
174	Paradoxical and Persistent Renal Impairment in Henoch-Schöenlein Purpura after High-Dose Immunoglobulin Therapy. <i>Nephron</i> , 1997, 76, 247-248.	0.6	17
175	Henoch-schöenlein purpura as clinical presentation of a myelodysplastic syndrome. <i>Clinical Rheumatology</i> , 1997, 16, 626-628.	2.2	17
176	Variants of the <i>IFI16</i> Gene Affecting the Levels of Expression of mRNA Are Associated with Susceptibility to Behçet Disease. <i>Journal of Rheumatology</i> , 2015, 42, 695-701.	2.0	17
177	Current and emerging diagnosis tools and therapeutics for giant cell arteritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 593-605.	3.0	17
178	Treatment of polymyalgia rheumatica. <i>Biochemical Pharmacology</i> , 2019, 165, 221-229.	4.4	17
179	Association of Functional Polymorphisms of KIR3DL1/DS1 With Behçet's Disease. <i>Frontiers in Immunology</i> , 2019, 10, 2755.	4.8	17
180	Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients. <i>Journal of Rheumatology</i> , 2021, 48, 741-750.	2.0	17

#	ARTICLE	IF	CITATIONS
181	Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. <i>Arthritis Research and Therapy</i> , 2021, 23, 231.	3.5	17
182	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. <i>PLoS ONE</i> , 2014, 9, e113476.	2.5	17
183	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 105-114.	0.8	17
184	Cutaneous vasculitis: an unusual presentation of sarcoidosis in adulthood: Case report. <i>Scandinavian Journal of Rheumatology</i> , 1998, 27, 80-82.	1.1	16
185	Medical management of polymyalgia rheumatica. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1077-1087.	1.8	16
186	Lack of association of <i>IL6R</i> rs2228145 and <i>IL6ST/gp130</i> rs2228044 gene polymorphisms with cardiovascular disease in patients with rheumatoid arthritis. <i>Tissue Antigens</i> , 2011, 78, 438-441.	1.0	16
187	Endothelial Progenitor Cells as a Potential Biomarker in Interstitial Lung Disease Associated with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 4098.	2.4	16
188	Imaging Tests in the Early Diagnosis of Giant Cell Arteritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3704.	2.4	16
189	Cardiovascular risk stratification in axial spondyloarthritis: carotid ultrasound is more sensitive than coronary artery calcification score to detect high-cardiovascular risk axial spondyloarthritis patients. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 73-80.	0.8	16
190	Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 37-42.	0.8	16
191	Biologic therapy in ANCA-negative vasculitis. <i>International Immunopharmacology</i> , 2015, 27, 213-219.	3.8	15
192	Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF- α antagonist therapy. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 538-45.	0.8	15
193	Magnetic resonance imaging: a useful technique in the diagnosis and follow up of focal myositis.. <i>Annals of the Rheumatic Diseases</i> , 1996, 55, 856-856.	0.9	14
194	Association Study of <i>MIA3</i> rs17465637 Polymorphism with Cardiovascular Disease in Rheumatoid Arthritis Patients. <i>DNA and Cell Biology</i> , 2012, 31, 1412-1417.	1.9	14
195	Cutaneous Vasculitis: A Rheumatologist Perspective. <i>Current Allergy and Asthma Reports</i> , 2013, 13, 545-554.	5.3	14
196	Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 941-943.	0.9	14
197	Thyroid autoimmunity in patients with hidradenitis suppurativa: a case-control study. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 642-644.	1.3	14
198	Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2017, 7, 10525.	3.3	14

#	ARTICLE	IF	CITATIONS
199	Genome-wide pathway analysis identifies VEGF pathway association with oral ulceration in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2017, 19, 138.	3.5	14
200	Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1025-1029.	3.4	14
201	Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the Tj ETQq1 1.0.7843144rgBT /C...	1.0	14
202	Combined use of QRISK3 and SCORE as predictors of carotid plaques in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 2801-2807.	1.9	14
203	Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 432-439.	0.9	14
204	Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 395-403.	3.4	14
205	Association of Trabecular Bone Score with Inflammation and Adiposity in Patients with Psoriasis: Effect of Adalimumab Therapy. <i>Journal of Osteoporosis</i> , 2016, 2016, 1-6.	0.5	13
206	Características clínicas, tratamiento y complicaciones oculares de uveítis anterior asociada y no asociada a HLA-B27. <i>Reumatología Clínica</i> , 2016, 12, 244-247.	0.5	13
207	Omentin: a biomarker of cardiovascular risk in individuals with axial spondyloarthritis. <i>Scientific Reports</i> , 2020, 10, 9636.	3.3	13
208	Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis: a multicentre study of 263 Caucasian patients. <i>Rheumatology</i> , 2021, 61, 299-308.	1.9	13
209	Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 387-394.	3.4	13
210	Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk. <i>Arthritis Research and Therapy</i> , 2021, 23, 162.	3.5	13
211	Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF- α antagonist therapy. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 365-71.	0.8	13
212	Analysis of the Interferon Gamma (rs2430561, +874T/A) Functional Gene Variant in Relation to the Presence of Cardiovascular Events in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2012, 7, e47166.	2.5	12
213	The lp13.3 genomic region -rs599839- is associated with endothelial dysfunction in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, R42.	3.5	12
214	Evaluation of the IL2/IL21, IL2RA and IL2RB genetic variants influence on the endogenous non-anterior uveitis genetic predisposition. <i>BMC Medical Genetics</i> , 2013, 14, 52.	2.1	12
215	SMAD3 rs17228212 Gene Polymorphism Is Associated with Reduced Risk to Cerebrovascular Accidents and Subclinical Atherosclerosis in Anti-CCP Negative Spanish Rheumatoid Arthritis Patients. <i>PLoS ONE</i> , 2013, 8, e77695.	2.5	12
216	Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis. <i>Scientific Reports</i> , 2017, 7, 40303.	3.3	12

#	ARTICLE	IF	CITATIONS
217	Association of circulating calprotectin with lipid profile in axial spondyloarthritis. <i>Scientific Reports</i> , 2018, 8, 13728.	3.3	12
218	Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF- β antagonist therapy. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 640-6.	0.8	12
219	Interleukin 1 beta (IL1 β) rs16944 genetic variant as a genetic marker of severe renal manifestations and renal sequelae in Henoch-Sch \ddot{u} lein purpura. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S84-8.	0.8	12
220	Carotid ultrasound in the cardiovascular risk stratification of patients with ankylosing spondylitis: results of a population-based study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 885-892.	0.8	12
221	Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 652-657.	0.8	12
222	Lack of association between Toll-like receptor 4 gene polymorphisms and giant cell arteritis. <i>Rheumatology</i> , 2011, 50, 1562-1568.	1.9	11
223	Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R154.	3.5	11
224	Investigation of aPON1 gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1749-1750.	0.9	11
225	Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Sch \ddot{u} lein purpura (IgA vasculitis). <i>Arthritis Research and Therapy</i> , 2015, 17, 286.	3.5	11
226	Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor- β therapy. <i>Journal of Dermatology</i> , 2016, 43, 389-394.	1.2	11
227	Vitamin D receptor GATG haplotype association with atherosclerotic disease in patients with rheumatoid arthritis. <i>Atherosclerosis</i> , 2016, 245, 139-142.	0.8	11
228	Significant sE-Selectin levels reduction after 6 months of anti-TNF- β therapy in non-diabetic patients with moderate-to-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 726-730.	2.2	11
229	Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 1344-1353.	2.0	11
230	Advances in the Treatment of Giant Cell Arteritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1588.	2.4	11
231	NPSR1 Gene Is Associated with Reduced Risk of Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 1166-1170.	2.0	10
232	Antitumor necrosis factor- β therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1265-1267.	0.9	10
233	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. <i>Rheumatology</i> , 2020, 59, 2043-2051.	1.9	10
234	Endothelial Progenitor Cells: Relevant Players in the Vasculopathy and Lung Fibrosis Associated with the Presence of Interstitial Lung Disease in Systemic Sclerosis Patients. <i>Biomedicines</i> , 2021, 9, 847.	3.2	10

#	ARTICLE	IF	CITATIONS
235	Osteoprotegerin CGA Haplotype Protection against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2014, 9, e106823.	2.5	10
236	Anti-TNF γ therapy and switching in severe uveitis related to Vogt-Koyanagi-Harada syndrome. <i>European Journal of Rheumatology</i> , 2017, 4, 226-228.	0.6	10
237	The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S34-S40.	0.8	10
238	Long-term followup of patients receiving combined therapy with cyclosporine and methotrexate. <i>Arthritis and Rheumatism</i> , 1998, 41, 1703-1704.	6.7	9
239	Medial tibial stress syndrome due to methotrexate osteopathy. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 832-833.	0.9	9
240	Role of the CCR5/ β 32CCR5 polymorphism in biopsy-proven giant cell arteritis. <i>Human Immunology</i> , 2011, 72, 458-461.	2.4	9
241	The 11q23.3 genomic region "rs964184" is associated with cardiovascular disease in patients with rheumatoid arthritis. <i>Tissue Antigens</i> , 2013, 82, 344-347.	1.0	9
242	<i>PDE3A-SLCO1C1</i> locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. <i>Pharmacogenomics</i> , 2014, 15, 1763-1769.	1.3	9
243	Lack of Association between <i>JAK3</i> Gene Polymorphisms and Cardiovascular Disease in Spanish Patients with Rheumatoid Arthritis. <i>BioMed Research International</i> , 2015, 2015, 1-11.	1.9	9
244	Coexistence of Hidradenitis Suppurativa with Autoimmune Thyroiditis: Report of Three Cases. <i>Dermatology</i> , 2016, 232, 162-164.	2.1	9
245	Association of retinol binding protein4 (RBP4) and ghrelin plasma levels with insulin resistance and disease severity in non-diabetic patients with hidradenitis suppurativa. <i>Experimental Dermatology</i> , 2020, 29, 828-832.	2.9	9
246	Carotid ultrasound is useful for the cardiovascular risk stratification in patients with hidradenitis suppurativa. <i>PLoS ONE</i> , 2018, 13, e0190568.	2.5	9
247	Moderate and High Disease Activity Predicts the Development of Carotid Plaque in Rheumatoid Arthritis Patients without Classic Cardiovascular Risk Factors: Six Years Follow-Up Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4975.	2.4	9
248	Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF- α antagonist therapy. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 749-55.	0.8	9
249	Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	9
250	Henoch-Schönlein purpura with hemorrhagic ascites and intestinal serositis. <i>Gastrointestinal Endoscopy</i> , 1996, 44, 624-625.	1.0	8
251	Patients with Ankylosing Spondylitis and Low Disease Activity because of Anti-TNF-Alpha Therapy Have Higher TRAIL Levels Than Controls: A Potential Compensatory Effect. <i>Mediators of Inflammation</i> , 2014, 2014, 1-6.	3.0	8
252	Documento de Recomendaciones de la Sociedad Española de Reumatología para el manejo clínico del paciente con artritis reumatoide que no puede utilizar metotrexato. <i>Reumatología Clínica</i> , 2017, 13, 127-138.	0.5	8

#	ARTICLE	IF	CITATIONS
253	Atherogenic index of plasma is associated with the severity of Hidradenitis Suppurativa: a case-control study. <i>Lipids in Health and Disease</i> , 2020, 19, 200.	3.0	8
254	Refractory polymyalgia rheumatica as presenting manifestation of large-vessel vasculitis associated to sarcoidosis. Successful response to adalimumab. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S94-7.	0.8	8
255	Lack of association between IL6 gene and Henoch-Schönlein purpura. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S141-2.	0.8	8
256	Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210932.	2.7	8
257	Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 612-620.	0.8	8
258	Análisis del polimorfismo rs20541 (R130Q) del gen de la IL-13 en pacientes con enfermedades inflamatorias crónicas asociadas al envejecimiento. <i>Reumatología Clínica</i> , 2012, 8, 321-327.	0.5	7
259	Cranial and extracranial giant cell arteritis share similar HLA-DRB1 association. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 897-901.	3.4	7
260	The Number of Traditional Cardiovascular Risk Factors Is Independently Correlated with Disease Activity in Patients with Psoriatic Arthritis. <i>Medicina (Lithuania)</i> , 2020, 56, 415.	2.0	7
261	Evaluation of serum omentin-1 and apelin concentrations in patients with hidradenitis suppurativa. <i>Postepy Dermatologii i Alergologii</i> , 2021, 38, 450-454.	0.9	7
262	Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110209.	2.7	7
263	A Review of the Dermatological Complications of Giant Cell Arteritis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2021, Volume 14, 303-312.	1.8	7
264	Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study. <i>Arthritis Research and Therapy</i> , 2021, 23, 111.	3.5	7
265	Epidemiology of sarcoidosis in northern Spain, 1999-2019: A population-based study. <i>European Journal of Internal Medicine</i> , 2021, 91, 63-69.	2.2	7
266	Desarrollo de una aplicación para teléfonos móviles (app) basada en la colaboración Sociedad Española de Reumatología/Sociedad Española de Medicina de Familia y Comunitaria para derivación de enfermedades autoinmunes sistémicas. <i>Reumatología Clínica</i> , 2020, 16, 373-377.	0.5	7
267	Lack of association between the protein tyrosine phosphatase non-receptor type 22 R263Q and R620W functional genetic variants and endogenous non-anterior uveitis. <i>Molecular Vision</i> , 2013, 19, 638-43.	1.1	7
268	Urticarial Vasculitis as Clinical Presentation of Megakaryocytic Leukemia. <i>Journal of Clinical Rheumatology</i> , 1996, 2, 366.	0.9	6
269	Letter to the Editor. <i>Lupus</i> , 2004, 13, 144-147.	1.6	6
270	No evidence of association between functional polymorphisms located within IL6R and IL6ST genes and Henoch-Schönlein purpura. <i>Tissue Antigens</i> , 2013, 82, 416-419.	1.0	6

#	ARTICLE	IF	CITATIONS
271	Refractory highly disfiguring lupus pernio: a dramatic and prolonged response to infliximab. <i>International Journal of Dermatology</i> , 2015, 54, e321-2.	1.0	6
272	Specific association of IL17A genetic variants with panuveitis. <i>British Journal of Ophthalmology</i> , 2015, 99, 566-570.	3.9	6
273	Drug therapies for polymyalgia rheumatica: a pharmacotherapeutic update. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1235-1244.	1.8	6
274	The role of biologics in the treatment of giant cell arteritis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 65-72.	3.1	6
275	Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. <i>Modern Rheumatology</i> , 2021, 31, 534-542.	1.8	6
276	TNF-related apoptosis-inducing ligand and cardiovascular disease in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 491-7.	0.8	6
277	Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 142-149.	0.8	6
278	Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152037.	3.4	6
279	Biomarkers of endothelial dysfunction and atherosclerosis in hidradenitis suppurativa. <i>Journal of Dermatology</i> , 2022, 49, 1052-1056.	1.2	6
280	Lack of association between the CXCL12 rs501120 polymorphism and cardiovascular disease in Spanish patients with rheumatoid arthritis. <i>Human Immunology</i> , 2012, 73, 543-546.	2.4	5
281	Analysis of the rs20541 (R130Q) Polymorphism in the IL-13 Gene in Patients With Elderly-associated Chronic Inflammatory Diseases. <i>Reumatología Clínica (English Edition)</i> , 2012, 8, 321-327.	0.3	5
282	IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy. <i>BioMed Research International</i> , 2014, 2014, 1-6.	1.9	5
283	A closer look at skin involvement in vasculitis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 186-187.	8.0	5
284	Relative Risk Chart Score for the Assessment of the Cardiovascular Risk in Young Patients with Ankylosing Spondylitis. <i>International Journal of Rheumatology</i> , 2018, 2018, 1-6.	1.6	5
285	Indicador compuesto para evaluar la calidad asistencial en el manejo de los pacientes con artritis reumatoide en las consultas externas de Reumatología. <i>Reumatología Clínica</i> , 2019, 15, 156-164.	0.5	5
286	Response to: Correspondence to Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases™ by Wu et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e244-e244.	0.9	5
287	Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 657-662.	3.4	5
288	Safety of secukinumab for the treatment of active ankylosing spondylitis. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-8.	2.4	5

#	ARTICLE	IF	CITATIONS
289	Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110337.	2.7	5
290	Predicting the risk of relapse in polymyalgia rheumatica: novel insights. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 225-232.	3.0	5
291	Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 1368-1382.	2.9	5
292	BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. <i>Scientific Reports</i> , 2021, 11, 11510.	3.3	5
293	Henoch-Schönlein purpura (IgA vasculitis): the paradox of the different incidence and clinical spectrum in children and adults. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 3-4.	0.8	5
294	Implication of osteoprotegerin and sclerostin in axial spondyloarthritis cardiovascular disease: study of 163 Spanish patients. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 302-309.	0.8	5
295	Epidemiological and genetic features of anti-3-hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: Single-center experience and literature review. <i>European Journal of Internal Medicine</i> , 2022, 101, 86-92.	2.2	5
296	Baker's Cyst as a Clinical Presentation of Brucellosis. <i>Clinical Infectious Diseases</i> , 1996, 22, 872-873.	5.8	4
297	A Nonsynonymous Functional Variant of the ITGAM Gene Is Not Involved in Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2011, 38, 2598-2601.	2.0	4
298	No Evidence of Association between Common Autoimmunity STAT4 and IL23R Risk Polymorphisms and Non-Anterior Uveitis. <i>PLoS ONE</i> , 2013, 8, e72892.	2.5	4
299	SAT0279...Tocilizumab in Refractory Aortitis: Study on 16 Patients and Literature Review. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 694.2-694.	0.9	4
300	Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151946.	3.4	4
301	Role of the rs6822844 gene polymorphism at the IL2-IL21 region in biopsy-proven giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S12-6.	0.8	4
302	Autoimmune disease-associated CD226 gene variants are not involved in giant cell arteritis susceptibility in the Spanish population. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S29-33.	0.8	4
303	Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF- α antagonist therapy. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 532-7.	0.8	4
304	Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF- α therapy. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 913-8.	0.8	4
305	Subclinical atherosclerosis is not increased in patients with non-radiographic axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 159-60.	0.8	4
306	Long-term survival of lung transplantation for interstitial lung disease associated with connective tissue diseases: a study of 26 cases from a referral centre. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 615-620.	0.8	4

#	ARTICLE	IF	CITATIONS
307	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 105-114.	0.8	4
308	Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 69-75.	0.8	4
309	Utility of tocilizumab in autoimmune eye diseases. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 789-799.	3.1	4
310	Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. <i>Lancet Rheumatology</i> , The, 2022, 4, e395-e406.	3.9	4
311	Influence of IL2RA rs2104286 Polymorphism in the Risk of Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2010, 37, 2331-2333.	2.0	3
312	Evaluation of a Shared Autoimmune Disease-associated Polymorphism of TRAF6 in Systemic Sclerosis and Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2012, 39, 1275-1279.	2.0	3
313	Single nucleotide polymorphisms at the 9p21.3 genomic region not associated with the risk of cardiovascular disease in patients with rheumatoid arthritis. <i>Tissue Antigens</i> , 2013, 82, 405-409.	1.0	3
314	Etanercept-induced hypertriglyceridemia during the treatment of recurrent aphthous stomatitis. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2013, 79, 432.	0.6	3
315	Two Functional Variants of IRF5 Influence the Development of Macular Edema in Patients with Non-Anterior Uveitis. <i>PLoS ONE</i> , 2013, 8, e76777.	2.5	3
316	The search for improvement in the sensitivity of temporal artery biopsy in giant cell arteritis. <i>Rheumatology</i> , 2015, 54, 379-380.	1.9	3
317	Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2608.	2.4	3
318	Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice. <i>Journal of Rheumatology</i> , 2021, 48, 1552-1558.	2.0	3
319	Biologic therapy in refractory neurobehavioural disease: a multicentre study of 41 patients and literature review. <i>Rheumatology</i> , 2022, 61, 4427-4436.	1.9	3
320	Subclinical aortitis after starting nivolumab in a patient with metastatic melanoma. A case of drug-associated aortitis?. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 171.	0.8	3
321	Tocilizumab in giant cell arteritis: differences between the GACTA trial and a multicentre series of patients from the clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 112-119.	0.8	3
322	The presence of both HLA-DRB1*04:01 and HLA-B*15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 21-26.	0.8	3
323	Angiogenic T Cells: Potential Biomarkers for the Early Diagnosis of Interstitial Lung Disease in Autoimmune Diseases?. <i>Biomedicines</i> , 2022, 10, 851.	3.2	3
324	SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis. <i>Diagnostics</i> , 2021, 11, 2363.	2.6	3

#	ARTICLE	IF	CITATIONS
325	Polymicrobial Prepatellar Septic Bursitis Caused by Brucella Abortus and Streptococcus Agalactiae. Journal of Clinical Rheumatology, 1997, 3, 120.	0.9	2
326	Interstitial Keratitis Secondary to Severe Hidradenitis Suppurativa Responding to Adalimumab. Cornea, 2012, 31, 206-206.	1.7	2
327	Use of positron emission tomography (PET) for the diagnosis of large-vessel vasculitis. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 372-377.	0.0	2
328	Detection of high cardiovascular risk patients with ankylosing spondylitis based on the assessment of abdominal aortic calcium as compared to carotid ultrasound. Arthritis Research and Therapy, 2018, 20, 195.	3.5	2
329	Recomendaciones de experto sobre el bloqueo de la interleucina 6 en pacientes con artritis reumatoide. Reumatología Clínica, 2020, 16, 272-281.	0.5	2
330	Association of Human Leukocyte Antigens Class II Variants with Susceptibility to Hidradenitis Suppurativa in a Caucasian Spanish Population. Journal of Clinical Medicine, 2020, 9, 3095.	2.4	2
331	The Performance of Vascular Age in the Assessment of Cardiovascular Risk of Patients with Rheumatoid Arthritis. Journal of Clinical Medicine, 2020, 9, 4065.	2.4	2
332	P184â€¦Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial. Rheumatology, 2021, 60, .	1.9	2
333	Vogt-Koyanagi-Harada disease in Spain. European Journal of Ophthalmology, 2022, 32, 1547-1554.	1.3	2
334	PTPN22 is not associated with Behçet's disease. Study spanning the complete gene region in the Spanish population and meta-analysis of the functional variant R620W. Clinical and Experimental Rheumatology, 2016, 34, S41-S45.	0.8	2
335	Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 69-75.	0.8	2
336	Long-term survival of renal transplantation in patients with lupus nephritis: experience from a single university centre. Clinical and Experimental Rheumatology, 2022, 40, 581-588.	0.8	2
337	Long-term outcome of total lymphoid irradiation in rheumatoid arthritis: Comment on the article by Westhovens et al. Arthritis and Rheumatism, 1998, 41, 945-946.	6.7	1
338	Disparate results in studies of adalimumab in the treatment of hidradenitis suppurativa: comment on the article by Amano <i>et al</i>. International Journal of Dermatology, 2013, 52, 380-381.	1.0	1
339	FRI0269â€¦COMPARATIVE STUDY OF INFLIXIMAB VERSUS ADALIMUMAB IN REFRACTORY UVEITIS DUE TO BEHÇET'S DISEASE. NATIONAL MULTICENTER STUDY OF 177 CASES. , 2019, , .		1
340	OP0029â€¦SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS. , 2019, , .		1
341	THU0288â€¦LONG-TERM FOLLOW-UP OF ANTI-IL6-RECEPTOR TOCILIZUMAB IN REFRACTORY UVEITIS IN PATIENTS WITH BEHÇET'S DISEASE. MULTICENTER STUDY OF 14 PATIENTS IN CLINICAL PRACTICE. , 2019, , .		1
342	THU0197â€¦MONOTHERAPY WITH UPADACITINIB IN MTX-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 48 WEEKS FROM THE SELECT-EARLY STUDY. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
343	FRI0202â€¦SHORT AND LONG-TERM FOLLOW-UP OF APREMILAST THERAPY IN REFRACTORY SKIN LUPUS LESIONS. , 2019, , .		1
344	FRI0612â€¦IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH IMMUNOTHERAPY. LONG-TERM FOLLOW-UP OF 102 PATIENTS FROM A REFERRAL SINGLE CENTER. , 2019, , .		1
345	Gastrointestinal involvement in adult IGA vasculitis. <i>Rheumatology</i> , 2020, 59, 2659-2660.	1.9	1
346	Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. <i>Scientific Reports</i> , 2021, 11, 16163.	3.3	1
347	Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 311-333.	2.4	1
348	Revisiting clinical differences between hypersensitivity vasculitis and Henoch-SchÅ¶nlein purpura in adults from a defined population. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S34-40.	0.8	1
349	Association of CCR5Î³32 and BehÅ¶set's disease: new data from a case-control study in the Spanish population and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S96-100.	0.8	1
350	Histopathologic differences between cutaneous vasculitis associated with severe bacterial infection and cutaneous vasculitis secondary to other causes: study of 52 patients. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S93-7.	0.8	1
351	Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1
352	Tocilizumab in BehÅ¶set's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 132, 37-42.	0.8	1
353	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1
354	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1
355	Giant cell arteritis and amyloidosis: comment on the article by Salvarani et al. <i>Arthritis and Rheumatism</i> , 1996, 39, 1073-1074.	6.7	0
356	Hypersensitivity vasculitis. <i>Lancet, The</i> , 1997, 350, 1036.	13.7	0
357	Towards a new clinical spectrum in giant cell arteritis. <i>Clinical Rheumatology</i> , 1997, 16, 639-639.	2.2	0
358	Successful Local Fibrinolytic Therapy for Arm Vein Thrombosis in Antiphospholipid Syndrome Secondary to Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 1998, 4, 106-108.	0.9	0
359	Chapter 24 Danazol Therapy. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008, 9, 265-271.	0.1	0
360	Effet bÅ¶nÅ¶frique du tocilizumab dans la pustulose palmoplantaire induite par anti-TNF-Î± au cours de la polyarthrite rhumatoÅ¶de. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2012, 79, 469-472.	0.0	0

#	ARTICLE	IF	CITATIONS
361	114.â€fSECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2). Rheumatology, 2017, 56, .	1.9	0
362	181â€fEfficacy and safety of ixekizumab at week 52 in biologic naÃve patients with active psoriatic arthritis (SPIRIT-P1). Rheumatology, 2018, 57, .	1.9	0
363	172â€fSecukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2. Rheumatology, 2018, 57, .	1.9	0
364	FRI0291â€f...RENAL TRANSPLANTATION DUE TO RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS (RPGN). COMPARATIVE STUDY WITH NON-AUTOIMMUNE TRANSPLANTATION AND LONG-TERM FOLLOW-UP. STUDY FROM A SINGLE TERTIARY CENTER. , 2019, , .		0
365	SAT0219â€f...EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS INDEPENDENTLY OF THE INICIAL PREDNISONE DOSE. , 2019, , .		0
366	AB0577â€f...TOCILIZUMAB IN GIANT CELL ARTERITIS. ROUTE OF ADMINISTRACION: INTRAVENOUS OR SUBCUTANEOUS. , 2019, , .		0
367	AB0319â€f...ABATACEPT IN RHEUMATOID ARTHRITIS WITH INTERSTITIAL LUNG DISEASE. A MULTICENTRE STUDY OF 181 PATIENTS. , 2019, , .		0
368	AB0612â€f...TEMPORAL ARTERY BIOPSYIN GIANT CELL ARTERITIS. INTERRELATION OF INFLAMMATORY PATTERNS WITH ANALYTICAL DATA AND CLINICAL MANIFESTATIONS. , 2019, , .		0
369	OP0304â€f...GENETIC AND FUNCTIONAL STUDY OF OMENTIN REGARDING CARDIOVASCULAR RISK IN AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
370	FRI0646â€f...EFFECT OF LONG-TERM MEDIUM-DOSE STEROID TREATMENT ON 18F-FDG PET/CT FINDINGS TO ASSESS VASCULAR AND MUSCULOESKELETAL INVOLVEMENT IN PATIENTSWITH POLYMYALGIA REUMATICA. , 2019, , .		0
371	SAT0506â€f...KAWASAKI DISEASE AND CARDIOVASCULAR OUTCOMES IN THE LAST 25 YEARS. STUDY OF 55 PATIENTS FROM A REFERAL HOSPITAL IN THE NORTH OF SPAIN. , 2019, , .		0
372	AB1098â€f...COMPARISON OF THE PERFORMANCE OF CLASSIFICATION/DIAGNOSTIC CRITERIA FOR POLYMYALGIA RHEUMATICA. SINGLE CENTERSTUDY OF 100 PATIENTS. , 2019, , .		0
373	FRI0270â€f...APREMILAST IN NON-ULCER MANIFESTATIONS IN BEHÃsetâ€™S DISEASE. MULTICENTER STUDY OF 32 CASES IN CLINICAL PRACTICE. , 2019, , .		0
374	AB1077â€f...ANTI-IL6-RECEPTOR TOCILIZUMAB IN GRAVESâ€™ ORBITOPATHY. MULTICENTER STUDY OF 46 PATIENTS IN CLINICAL PRACTICE. , 2019, , .		0
375	THU0283â€f...PATIENT ACCEPTABLE SYMPTOMS STATE (PASS) QUESTIONNAIRE APPLICATION IN THE COHORT OF SLE PATIENTS FROM THE SPANISH SOCIETY OF RHEUMATOLOGY (RELESSER): ASSOCIATION WITH ACTIVITY INDEX. , 2019, , .		0
376	THU0292â€f...EXTRACRANIAL VESSEL INVOLVEMENT IN PATIENTS WITH GIANT CELL ARTERITIS. , 2019, , .		0
377	FRI0276â€f...TIME OF DISEASE EVOLUTION AND EFFICACY OF TOCILIZUMAB IN GIANT CELL ARTERITIS. , 2019, , .		0
378	FRI0277â€f...ISCHEMIC AND SYSTEMIC SYMPTOMS IN GIANT CELL ARTERITIS PATIENTS, RESPONSE TO TOCILIZUMAB. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
379	FRI0006â€¦PROTECTIVE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) RS2495477 POLYMORPHISM IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SUBCLINICAL ATHEROSCLEROSIS. , 2019, , .		0
380	FRI0038â€¦HERPES ZOSTER IN RHEUMATOID ARTHRITIS. PROSPECTIVE SINGLE CENTER STUDY OF 390 RA PATIENTS FOR 5YEARS. , 2019, , .		0
381	FRI0253â€¦RENAL TRANSPLANTATION IN LUPUS NEPHRITISVS NON-AUTOIMMUNE TRANSPLANTATION. LONG TERM FOLLOW-UP. STUDY FROM A SINGLE TERTIARY CENTER. , 2019, , .		0
382	FRI0348â€¦USE OF INTRAVENOUS IMMUNOGLOBULIN THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS: A SPANISH MULTICENTER EXPERIENCE. , 2019, , .		0
383	SAT0199â€¦POLYAUTOIMMUNITY IN SYSTEMIC LUPUS ERYTHEMATOSUS. DATA FROM A LARGE SPANISH COHORT: SPANISH SOCIETY OF RHEUMATOLOGY REGISTRY OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (RELESSER).. , 2019, , .		0
384	OP0169â€¦LONG-TERM SURVIVAL IN LUNG TRANSPLANTATION FOR INTERSTITIAL LUNG DISEASE ASSOCIATED WITH CONECTIVE TISSUE DISEASES. STUDY OF 26 CASES OF A SINGLE CENTER. , 2019, , .		0
385	SAT0220â€¦USE OF TOCILIZUMAB IN AORTITIS. A MULTICENTER STUDY OF 79 PATIENTS. , 2019, , .		0
386	THU0581â€¦BIOLOGICAL THERAPY IN NON ISCHAEMIC OPTIC NEURITIS ASSOCIATED TO IMMUNE-MEDIATED INFLAMMATORY DISEASES. MULTICENTER STUDY. , 2019, , .		0
387	THU0313â€¦COMPARATIVE STUDY OF CLINICAL, ANALYTICAL AND VASCULAR 18F-FDG LIPTAKE EVOLUTION IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH METHOTREXATE VS TOCILIZUMAB. , 2019, , .		0
388	THU0566â€¦OCULAR FEATURES IN 381 PATIENTS WITH SYSTEMIC SARCOIDOSIS AND ITS CORRELATION WITH THE IWOS CRITERIA. STUDY IN A UNIVERSITY HOSPITAL. , 2019, , .		0
389	FRI0379â€¦LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL. , 2019, , .		0
390	THU0584â€¦RHEUMATOLOGICAL IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH IMMUNOTHERAPY IN SOLID ORGAN TUMOR. STUDY OF 102 CASES FROM A REFERRAL SINGLE CENTER FOR LAST 4 YEARS. , 2019, , .		0
391	SAT0235â€¦BIOLOGICAL THERAPYIN NEUROBEHÄ±ET. MULTICENTER STUDY OF 29 PATIENTS. , 2019, , .		0
392	FRI0604â€¦SYSTEMIC SARCOIDOSIS. STUDY OF 381 PATIENTS FROM A TERTIARY UNIVERSITY HOSPITAL IN THE NORTH OF SPAIN. , 2019, , .		0
393	AB0762â€¦TREATMENT WITH TOFACITINIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF CLINICAL PRACTICE. , 2019, , .		0
394	SAT0215â€¦APREMILAST IN REFRACTORY ORAL AND/OR GENITAL ULCERS IN BEHÄ±ETâ€™S DISEASE. MULTICENTER STUDY OF 49 CASES IN CLINICAL PRACTICE. , 2019, , .		0
395	Author's response to Drs. Marasca etÄ±al . and Drs. De Vita and Melnik: hidradenitis suppurativa, insulin resistance and mTOR. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e109.	2.4	0
396	Aportaciones del registro de lupus de la Sociedad EspaÃ±ola de ReumatologÃ±a (RELESSER) al conocimiento del lupus eritematoso sistÃ©mico en EspaÃ±a. ReumatologÃ±a ClÃ±nica, 2021, 17, 245-249.	0.5	0

#	ARTICLE	IF	CITATIONS
397	Cranial and extracranial giant cell arteritis do not have different HLA-DRB1 and HLA-B association in Caucasian individuals. <i>Arthritis Research and Therapy</i> , 2021, 23, 268.	3.5	0
398	Tocilizumab for the treatment of rheumatoid arthritis. <i>Clinical Practice (London, England)</i> , 2012, 9, 255-268.	0.1	0
399	Análisis estadístico de los nombres comerciales de maderas en un país (España). <i>Madera Bosques</i> , 2014, 20, 59-70.	0.2	0
400	Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 182-187.	0.8	0
401	Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 612-620.	0.8	0
402	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
403	Long-term survival of renal transplantation in patients with lupus nephritis: experience from a single university centre. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
404	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0